STM Journals Peer-reviewed research from Consortium e-Learning Network

Research & Reviews: A Journal of Drug Design & Discovery Review Article

Nanomedicine in the Tumor Microenvironment: Physiological Modulation Through Tissue Engineering Approaches

  1. Parmar Harshul Department of Pharmacy, School of Pharmacy, Rai University, Ahmedabad
  2. Varma Vishnu Department of Pharmacy, School of Pharmacy, Rai University, Ahmedabad
  3. Shubham Singh Department of Pharmaceutics, School of Pharmacy, Rai University, Ahmedabad

Abstract

The integration of nanomedicine and tissue engineering offers transformative strategies for cancer therapy by directly modulating the physiological processes within the tumor microenvironment (TME). This review emphasizes recent advances in nanomedicine that enable precise drug delivery, controlled release, and real-time monitoring of key physiological parameters influencing tumor progression, angiogenesis, and immune evasion. Tissue-engineered 3D tumor models provide physiologically relevant platforms that better mimic in vivo conditions than traditional 2D cultures, facilitating enhanced understanding of tumor biology and therapy resistance. Advances in stimuli-responsive nanoparticles, organ-on-chip platforms, and biomaterials allow researchers to study and manipulate the TME in ways that have direct translational potential for personalized medicine. By focusing on the physiological mechanisms and applied approaches, this review underscores the synergistic role of nanomedicine and tissue engineering in advancing therapeutic strategies and improving cancer treatment outcomes.

Keywords

References (92)

  1. Lee S, Kim G, Lee J, Lee AC, Kwon S. Mapping cancer biology in space: applications and perspectives on spatial omics for oncology. Molecular Cancer. 2024;23(1). doi:10.1186/s12943-024-01941-z
  2. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Communication and Signaling. 2011;9(1):18. doi:10.1186/1478-811x-9-18
  3. Ma H, Xu H, Qin J. Biomimetic tumor microenvironment on a microfluidic platform. Biomicrofluidics. 2013;7(1). doi:10.1063/1.4774070
  4. Dzobo K. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. OMICS: A Journal of Integrative Biology. 2020;24(4):175-179. doi:10.1089/omi.2020.0019
  5. Guller AE, Grebenyuk PN, Shekhter AB, Zvyagin AV, Deyev SM. Bioreactor-Based Tumor Tissue Engineering. Acta Naturae. 2016;8(3):44-58. doi:10.32607/20758251-2016-8-3-44-58
  6. Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 2016;8(3):3933-3945. doi:10.18632/oncotarget.13907
  7. Zhang Q, Lou Y, Fang H, Sun S, Jin R, Ji Y, et al. Cancer‑associated fibroblasts under therapy‑induced senescence in the tumor microenvironment (Review). Experimental and Therapeutic Medicine. 2024;27(4). doi:10.3892/etm.2024.12438
  8. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Letters. 2017;387:61-68. doi:10.1016/j.canlet.2016.01.043
  9. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. Journal of Biomedical Science. 2018;25(1). doi:10.1186/s12929-018-0426-4
  10. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Research. 2009;19(2):156-172. doi:10.1038/cr.2009.5
  11. Dai X, Guo X, Liu J, Cheng A, Peng X, Jia R, et al. Circular RNA circGRAMD1B inhibits gastric cancer progression by sponging miR-130a-3p and regulating PTEN and p21 expression. Aging. 2019;11(23):9689–708. doi:10.18632/aging.102415.
  12. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery. 2018;18(2):99-115. doi:10.1038/s41573-018-0004-1
  13. Ramamonjisoa N, Ackerstaff E. Characterization of the Tumor Microenvironment and Tumor–Stroma Interaction by Non-invasive Preclinical Imaging. Frontiers in Oncology. 2017;7. doi:10.3389/fonc.2017.00003
  14. Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Science. 2017;108(10):1921-1926. doi:10.1111/cas.13336
  15. Watanabe K, Panchy N, Noguchi S, Suzuki H, Hong T. Combinatorial perturbation analysis reveals divergent regulations of mesenchymal genes during epithelial-to-mesenchymal transition. NPJ Syst Biol Appl. 2019;5(1). doi:10.1038/s41540-019-0091-9.
  16. Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nature Genetics. 2017;49(5):708-718. doi:10.1038/ng.3818
  17. Lee SY, Jeong EK, Jeon HM, Kim CH. Implications of epithelial-mesenchymal transition in cancer stem cells: therapeutic targets and clinical relevance. Expert Rev Mol Sci. 2014;16(3):289–300. doi:10.1586/14737175.2014.884927.
  18. Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43–84. doi:10.1016/bs.acr.2018.11.002.
  19. Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. The International Journal of Biochemistry & Cell Biology. 2019;107:38-52. doi:10.1016/j.biocel.2018.12.001
  20. Batlle E, Clevers H. Cancer stem cells revisited. Nature Medicine. 2017;23(10):1124-1134. doi:10.1038/nm.4409
  21. Kreso A, Dick JE. Evolution of the Cancer Stem Cell Model. Cell Stem Cell. 2014;14(3):275-291. doi:10.1016/j.stem.2014.02.006
  22. Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sciences. 2019;234:116781. doi:10.1016/j.lfs.2019.116781
  23. Fontana F, Carollo E, Melling GE, Carter DRF. Extracellular Vesicles: Emerging Modulators of Cancer Drug Resistance. Cancers. 2021;13(4):749. doi:10.3390/cancers13040749
  24. Vasconcelos MH, Caires HR, Ābols A, Xavier CPR, Linē A. Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance. Drug Resistance Updates. 2019;47:100647. doi:10.1016/j.drup.2019.100647
  25. Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, et al. Inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an anti-PDGFRβ aptamer. Theranostics. 2017;7(15):3595–607. doi:10.7150/thno.20481.
  26. Nandy SB, Arumugam A, Subramani R, Pedroza D, Hernandez K, Saltzstein E, et al. MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the Hippo signaling pathway. Oncotarget. 2015;6(19):17366–78. doi:10.18632/oncotarget.4020.
  27. O’Conor CJ, Chen T, González I, Cao D, Peng Y. Cancer Stem Cells in Triple-Negative Breast Cancer: a Potential Target and Prognostic Marker. Biomarkers in Medicine. 2018;12(7):813-820. doi:10.2217/bmm-2017-0398
  28. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Molecular Oncology. 2010;4(5):404-419. doi:10.1016/j.molonc.2010.06.005
  29. Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews‐Elger K, et al. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ‐secretase inhibitor drug responses. EMBO Molecular Medicine. 2013;5(10):1502-1522. doi:10.1002/emmm.201302558
  30. Lindner U, Kramer J, Behrends J, Driller B, Wendler NO, Boehrnsen F, et al. Improved proliferation and differentiation capacity of human mesenchymal stromal cells cultured with basement-membrane extracellular matrix proteins. Cytotherapy. 2010;12(8):992–1005. doi:10.3109/14653249.2010.501791.
  31. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, et al. Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences. 2011;109(8):2772-2777. doi:10.1073/pnas.1017626108
  32. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumor Biology. 2014;35(5):3945-3951. doi:10.1007/s13277-013-1561-x
  33. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Research. 2016;18(1). doi:10.1186/s13058-016-0740-2
  34. Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell. 2018;172(4):841-856.e16. doi:10.1016/j.cell.2018.01.009
  35. Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal Cells in Colon Cancer. Gastroenterology. 2017;152(5):964-979. doi:10.1053/j.gastro.2016.11.049
  36. Tao L, Huang G, Song H, Chen Y, Chen L. Cancer associated fibroblasts: An essential role in the tumor microenvironment. Oncology Letters. 2017;14(3):2611-2620. doi:10.3892/ol.2017.6497
  37. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes & Development. 2016;30(9):1002-1019. doi:10.1101/gad.279737.116
  38. Wang X, Sun W, Shen W, Xia M, Chen C, Xiang D, et al. Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. Journal of Hepatology. 2016;64(6):1283-1294. doi:10.1016/j.jhep.2016.01.019
  39. Quante M, Tu SP, Tomita H, Gonda T, Wang SSW, Takashi S, et al. Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth. Cancer Cell. 2011;19(2):257-272. doi:10.1016/j.ccr.2011.01.020
  40. Kalluri R. The biology and function of fibroblasts in cancer. Nature Reviews Cancer. 2016;16(9):582-598. doi:10.1038/nrc.2016.73
  41. Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 2022;82(6):1630–44. doi:10.1158/0008-5472.CAN-21-1305.
  42. Malfitano AM, Pisanti S, Napolitano F, Di Somma S, Martinelli R, Portella G. Tumor-Associated Macrophage Status in Cancer Treatment. Cancers. 2020;12(7):1987. doi:10.3390/cancers12071987
  43. Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.583084
  44. Komohara Y, Fujiwara Y, Ohnishi K, Takeya M. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Advanced Drug Delivery Reviews. 2016;99:180-185. doi:10.1016/j.addr.2015.11.009
  45. Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity. 2014;41(1):49-61. doi:10.1016/j.immuni.2014.06.010
  46. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Frontiers in Physiology. 2014;5. doi:10.3389/fphys.2014.00075
  47. Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. Journal of Experimental Medicine. 2015;212(4):435-445. doi:10.1084/jem.20150295
  48. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15(1). doi:10.1186/s12885-015-1546-9
  49. Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated Macrophages in Cancer. Trends in Immunology. 2019;40(4):310-327. doi:10.1016/j.it.2019.02.003
  50. Chanmee T, Ontong P, Konno K, Itano N. Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. Cancers. 2014;6(3):1670-1690. doi:10.3390/cancers6031670
  51. He Z, Ding J, Huie M, Yang Y, Zhang Y. Role of tumor-associated macrophages in the development of gastrointestinal tumors. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188616. doi:10.1016/j.bbcan.2021.188616.
  52. Jang J, Kim J, Lee K, Kim C. Tumor-associated macrophage as a prognostic biomarker of non-small cell lung cancer: a meta-analysis. Sci Rep. 2020;10(1):15203. doi:10.1038/s41598-020-72181-w.
  53. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer. 2008;8(8):618-631. doi:10.1038/nrc2444
  54. Lin EY, Pollard JW. Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer. Cancer Research. 2007;67(11):5064-5066. doi:10.1158/0008-5472.can-07-0912
  55. Hussain M, Adah D, Tariq M, Lu Y, Zhang J, Liu J. CXCL13/CXCR5 signaling axis in cancer. Life Sciences. 2019;227:175-186. doi:10.1016/j.lfs.2019.04.053
  56. Wang L, Zhu B, Zhang M, Wang X. Roles of CCL3 in tumor microenvironment. Cancer Manag Res. 2020;12:6163–72. doi:10.2147/CMAR.S258237.
  57. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes & Development. 2011;25(23):2465-2479. doi:10.1101/gad.180331.111
  58. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130-133. doi:10.1038/nature13862
  59. Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schröder CP. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? Cancer Treatment Reviews. 2018;70:178-189. doi:10.1016/j.ctrv.2018.08.010
  60. Ruffell B, Coussens LM. Macrophages and Therapeutic Resistance in Cancer. Cancer Cell. 2015;27(4):462-472. doi:10.1016/j.ccell.2015.02.015
  61. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cellular Immunology. 2017;316:1-10. doi:10.1016/j.cellimm.2017.04.005
  62. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature Reviews Drug Discovery. 2018;17(12):887-904. doi:10.1038/nrd.2018.169
  63. Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. Frontiers in Oncology. 2020;10. doi:10.3389/fonc.2020.00188
  64. Ovais M, Guo M, Chen C. Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages. Advanced Materials. 2019;31(19). doi:10.1002/adma.201808303
  65. Ramesh A, Brouillard A, Kumar S, Nandi D, Kulkarni A. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 2020;227:119559. doi:10.1016/j.biomaterials.2019.119559
  66. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. Cancer Cell. 2014;25(6):846-859. doi:10.1016/j.ccr.2014.05.016
  67. Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell. 2017;32(5):654-668.e5. doi:10.1016/j.ccell.2017.10.005
  68. Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38(5):685-700.e8. doi:10.1016/j.ccell.2020.09.001
  69. Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proceedings of the National Academy of Sciences. 2018;115(17). doi:10.1073/pnas.1720948115
  70. Kumar S, Saha S, Singh K, Singh T, Mishra AK, Dubey BN, et al. Beneficial Effects of Spirulina on Brain Health: A Systematic Review. Current Functional Foods. 2025;3(1). doi:10.2174/0126668629269256231222092721
  71. Professor and Head, Dept. of Pharmacognosy, The Erode College of Pharmacy, Perundurai Main Road, Veppampalayam, Erode-638112, Tamilnadu, India, RaviKKumar VR, Rathi S, Professor & Principal, School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, Singh S, Assistant Professor, School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, et al. A Comprehensive Review on Ulcer and Their Treatment. Chinese Journal of Applied Physiology. 2023;39:e20230006. doi:10.62958/j.cjap.2023.006
  72. Singh V, Arora S, Akram W, Alam S, Kumari L, Kumar N, et al. Involvement of Molecular Mechanism and Biological Activities of Pemirolast: A Therapeutic Review. New Emirates Medical Journal. 2024;05. doi:10.2174/0102506882308410240607053814
  73. Professor, Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, Rajput DS, Gupta N, Professor and Dean, Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, Singh S, Ph.D. Research Scholar, Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, et al. A Comprehensive Review: Personalized Medicine for Rare Disease Cancer Treatment. Chinese Journal of Applied Physiology. 2023;39:e20230008. doi:10.62958/j.cjap.2023.008
  74. Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, MP. India, Singh S, Chaurasia A, Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, MP. India, Rajput DS, Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, MP. India, et al. Mucoadhesive Drug Delivery System and There Future Prospective: Are a Promising Approach for Effective Treatment? Chinese Journal of Applied Physiology. 2023;39:e20230005. doi:10.62958/j.cjap.2023.005
  75. Kumar S, Saha S, Sharma B, Singh S, Shukla P, Mukherjee S, et al. The Role of Resveratrol in Alzheimer's Disease: A Comprehensive Review of Current Research. Current Functional Foods. 2024;2(2). doi:10.2174/0126668629269244231127071411
  76. Sigmapharm laboratories llc, Bensalem, Pennsylvania, USA, Patel S, Y I, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai-600048, Tamilnadu, India, Singh S, GSVM Medical College (MBBS 3rd year Student), Kanpur-208002, Uttar Pradesh, India, et al. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. Chinese Journal of Applied Physiology. 2024:e20240031. doi:10.62958/j.cjap.2024.031
  77. Assistant Professor, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, India, Vaghela MC, Rathi S, Professor and Principal, School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, Shirole RL, Associate Professor, Department of Pharmacology, DCS’s A.R.A. College of Pharmacy, Nagaon, Dhule (MS) India, et al. Leveraging AI and Machine Learning in Six-Sigma Documentation for Pharmaceutical Quality Assurance. Chinese Journal of Applied Physiology. 2024;40:e20240005. doi:10.62958/j.cjap.2024.005
  78. Sigmapharm laboratories llc, Bensalem, Pennsylvania, USA, Patel S, Y I, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai-600048, Tamilnadu, India, Singh S, GSVM Medical College (MBBS 3rd year Student), Kanpur-208002, Uttar Pradesh, India, et al. Recent Innovations and Future Perspectives in Transferosomes for Transdermal Drug Delivery in Therapeutic and Pharmacological Applications. Chinese Journal of Applied Physiology. 2024:e20240031. doi:10.62958/j.cjap.2024.031
  79. Kumar S, Saha S, Pathak D, Singh T, Kumar A, Singh K, et al. Cholesterol Absorption Inhibition by Some Nutraceuticals. Recent Advances in Food, Nutrition & Agriculture. 2024;16(1):2-11. doi:10.2174/012772574x285280240220065812
  80. Singh, S., Chaurasia, A., Rajput, D. S., & Gupta, N. (2024). An overview on mucoadhesive buccal drug delivery systems & approaches: A comprehensive review. African Journal of Biological Sciences (South Africa), 6(5), 522–541, doi:10.33472/AFJBS.6.5.2024.522-541
  81. Kumar S, Singh S, Rajput D, Sharma B, Chaturvedi K, Singh N, et al. Pharmacological Approaches and Herbal Interventions for Alzheimer's Disease. The Natural Products Journal. 2024;14(8). doi:10.2174/0122103155275266231123090138
  82. Department of Pharmacognosy, The Erode College of Pharmacy,Erode, Tamilnadu, India-638112, Ravikkumar VR, Patel BD, Department of Pharmaceutical Chemistry & Quality Assurance, School of Pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, Gujarat, India-382260, Rathi S, Department of Pharmaceutics, School of Pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, Gujarat, India-382260, et al. Formulation and Evaluation of Drumstick Leaves Tablet as An Immunomodulator. Chinese Journal of Applied Physiology. 2024;40:e20240004. doi:10.62958/j.cjap.2024.004
  83. Sharma, A., Bara, G., Keshamma, E., Sharma, B., Singh, S., Singh, S. P., Parashar, T., Rathore, H. S., Sarma, S. K., & Rawat, S. (2023). Cancer biology and therapeutics: A contemporary review. Journal of Cardiovascular Disease Research, 14(10), 1229-1247.
  84. DEWANGAN HK, SINGH S, MISHRA R, DUBEY RK. A REVIEW ON APPLICATION OF NANOADJUVANT AS DELIVERY SYSTEM. International Journal of Applied Pharmaceutics. 2020:24-33. doi:10.22159/ijap.2020v12i4.36856
  85. Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, Singh S, Chaurasia A, Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, Gupta N, Patel College of Pharmacy, Madhyanchal Professional University, Ratibad, Bhopal, MP. India, et al. Effect of Formulation Parameters on Enalapril Maleate Mucoadhesive Buccal Tablet Using Quality by Design (QbD) Approach. Chinese Journal of Applied Physiology. 2024;40:e20240003. doi:10.62958/j.cjap.2024.003
  86. Deshpande Padmanabh Bhagwan. Formulation and Optimization of Piroxicam Loaded Nanoparticles for Topical Application Using Design of Experiments (DoE). Cuestiones de Fisioterapia. 2025;54(4):109-119. doi:10.48047/bsa4k692
  87. Patel SK, Prathyusha S, Kasturi M, Godse KC, Singh R, Rathi S, et al. Optimizing Irbesartan Fast Dissolving Tablets Using Natural Polysaccharides for Enhanced Drug Delivery and Patient Compliance. International Research Journal of Multidisciplinary Scope. 2025;06(01):1181-1190. doi:10.47857/irjms.2025.v06i01.02542
  88. Formulation, optimization and evaluation of mucoadhesive buccal tablets of ondansetron for enhanced bioavailability and sustained drug release. Biochemical and Cellular Archives. 2025;25(1). doi:10.51470/bca.2025.25.1.1063
  89. School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, Singh S, Rathi S, School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, Singh S, United Institute of Technology (B.Tech-EC), Prayagraj, Uttar Pradesh, India, et al. CD3-Bispecific Monoclonal Antibodies: A Novel Therapeutic Approach for Complex and Multifactorial Diseases. Chinese Journal of Applied Physiology. 2025:e20250019. doi:10.62958/j.cjap.2025.019
  90. School of Pharmacy, Rai University, Ahmedabad, Gujarat, India, Singh S, Rajput DS, Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, MP, India, Gupta N, Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, MP, India, et al. A Brief Review on Transdermal Patches. Chinese Journal of Applied Physiology. 2025:e20250013. doi:10.62958/j.cjap.2025.013
  91. Rathi SG, Kamani K, Patel B, Singh S, Patel Y. Formulation and Evaluation of Voriconazole Emulgel. Research Journal of Pharmacy and Technology. 2025:3917-3922. doi:10.52711/0974-360x.2025.00563
  92. vagela K, Patel A, Bhagwan DP, Shah A, Shirole RL, Rathi S. Formulation and Evaluation of Anti-Protozoal Drug for Emulgel Using New Polymer. Research Journal of Pharmacy and Technology. 2025:4833-4838. doi:10.52711/0974-360x.2025.00697
Support